Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsJason Kwah, MD, MSc
Assistant Professor AdjunctAbout
Research
Publications
2025
CO178 Dupilumab Improves Health-Related Quality Of Life And Asthma Control In Patients With And Without Coexisting Type 2 Conditions: Results From The RAPID Study
Mosnaim G, Price D, Côté A, Plaza V, Xia C, Awad H, Kwah J. CO178 Dupilumab Improves Health-Related Quality Of Life And Asthma Control In Patients With And Without Coexisting Type 2 Conditions: Results From The RAPID Study. Value In Health 2025, 28: s56. DOI: 10.1016/j.jval.2025.04.263.Peer-Reviewed Original ResearchCO143 Outcomes In Patients With Asthma and Coexisting Allergic Rhinitis Who Started Dupilumab Treatment In Real-World Clinical Practice: A RAPID Registry Study
Côté A, Muñoz X, Price D, Mosnaim G, Xia C, Awad H, Kwah J. CO143 Outcomes In Patients With Asthma and Coexisting Allergic Rhinitis Who Started Dupilumab Treatment In Real-World Clinical Practice: A RAPID Registry Study. Value In Health 2025, 28: s49. DOI: 10.1016/j.jval.2025.04.228.Peer-Reviewed Original ResearchDupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results From the RAPID Study
Cote A, Mosnaim G, Lugogo N, Price D, Plaza V, Changming X, Awad H, Kwah J. Dupilumab Improves Health-related Quality of Life and Asthma Control in Patients With and Without Coexisting Type 2 Conditions: Results From the RAPID Study. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a1399-a1399. DOI: 10.1164/ajrccm.2025.211.abstracts.a1399.Peer-Reviewed Original ResearchElevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma
De Llano L, Guilleminault L, Canonica G, Pavord I, Couillard S, Porsbjerg C, Brusselle G, Castro M, Bourdin A, Altincatal A, Kwah J, Ledanois O. Elevated inflammatory type 2 biomarkers at baseline predict multicomponent clinical remission following dupilumab treatment in patients with moderate-to-severe asthma. Revue Française D'Allergologie Et D'Immunologie Clinique 2025, 65: 104323. DOI: 10.1016/j.reval.2025.104323.Peer-Reviewed Original ResearchModerate-to-severe asthmaClinical remissionDupilumab treatmentDrivers of type 2 inflammationType 2 biomarkersFractional exhaled nitric oxideOral corticosteroid useType 2 inflammationBaseline blood eosinophilsHuman monoclonal antibodyAdd-on dupilumabImprove lung functionExhaled Nitric OxidePost Hoc AnalysisPlacebo Q2WPlacebo recipientsBaseline FeNORemission rateCorticosteroid useDupilumabFeNO levelsRemissionBlood eosinophilsPlaceboLung functionEvaluating Penicillin Allergy Clinical Decision-Making Tools to Enhance Penicillin Allergy De-labeling
Su C, Belmont A, Kuster J, Liao J, Kwah J. Evaluating Penicillin Allergy Clinical Decision-Making Tools to Enhance Penicillin Allergy De-labeling. Journal Of Allergy And Clinical Immunology 2025, 155: ab5. DOI: 10.1016/j.jaci.2024.12.021.Peer-Reviewed Original ResearchBaseline Characteristics Associated With Multicomponent Clinical Remission Following Dupilumab Treatment In Patients With Moderate-To-Severe Asthma
Canonica G, de Llano L, Pavord I, Couillard S, Porsbjerg C, Brusselle G, Castro M, Peters A, Bourdin A, Altincatal A, Kwah J, Ledanois O. Baseline Characteristics Associated With Multicomponent Clinical Remission Following Dupilumab Treatment In Patients With Moderate-To-Severe Asthma. Journal Of Allergy And Clinical Immunology 2025, 155: ab20. DOI: 10.1016/j.jaci.2024.12.068.Peer-Reviewed Original ResearchReal-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study
Bourdin A, Canonica G, Virchow J, Borsos K, Stanford R, Ledanois O, Kwah J, Ge W, Huynh L, Duh M, Boca A, Cheng W. Real-World Effectiveness of Dupilumab vs Omalizumab, Benralizumab, and Mepolizumab on Lung Function Improvement in Severe Asthma Patients: Findings from the EU-ADVANTAGE Study. Journal Of Allergy And Clinical Immunology 2025, 155: ab234. DOI: 10.1016/j.jaci.2024.12.720.Peer-Reviewed Original Research
2024
PCR104 Asthma Characteristics and Patient-Reported Outcomes in Patients With Atopic Dermatitis in the Rapid Registry of Dupilumab Use in a Real-World Setting
Mosnaim G, Peters A, Lugogo N, Price D, Côté A, Plaza V, Xia C, Gómez L, Kwah J. PCR104 Asthma Characteristics and Patient-Reported Outcomes in Patients With Atopic Dermatitis in the Rapid Registry of Dupilumab Use in a Real-World Setting. Value In Health 2024, 27: s525. DOI: 10.1016/j.jval.2024.10.3347.Peer-Reviewed Original ResearchRWD21 Characteristics of Patients With Asthma and History of Coexisting Allergic Rhinitis Initiating Dupilumab in Real-World Clinical Practice: The Rapid Registry Study
Peters A, Côté A, Muñoz X, Lugogo N, Price D, Mosnaim G, Xia C, Gómez L, Kwah J. RWD21 Characteristics of Patients With Asthma and History of Coexisting Allergic Rhinitis Initiating Dupilumab in Real-World Clinical Practice: The Rapid Registry Study. Value In Health 2024, 27: s575. DOI: 10.1016/j.jval.2024.10.3579.Peer-Reviewed Original ResearchImproving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention
Belmont A, Son M, Hyman J, You L, Su C, Kashyap N, Topal J, McManus D, Martinello R, Kwah J. Improving cefazolin administration for surgical prophylaxis in reported penicillin allergy: A retrospective study of a health system intervention. Journal Of Allergy And Clinical Immunology Global 2024, 4: 100377. PMID: 39830990, PMCID: PMC11742594, DOI: 10.1016/j.jacig.2024.100377.Peer-Reviewed Original ResearchPenicillin allergy labelHospital-wide guidelinesSurgical site infectionAllergy labelsSurgical patientsSevere allergic reactionsSurgical prophylaxisSite infectionAssociated with increased rates of surgical site infectionRate of surgical site infectionMulti-drug resistant infectionsAllergic reactionsPrevent surgical site infectionsFirst-line antibioticsFirst-line prophylaxisAdministration of cefazolinAssociated with increased ratesRetrospective cohort studyGuideline-directed therapyAdult surgical patientsPre-intervention groupPost-intervention groupPenicillin allergyPerioperative outcomesCefazolin administration
Academic Achievements & Community Involvement
News
News
- September 03, 2025
Yale Researchers Uncover Biological Differences in Asthma Between Males and Females
- December 14, 2023
Solving the Drug Allergy Puzzle: A Q&A With Ami Belmont
- October 12, 2023
Welcome New Staff, Faculty, Postdocs & Postgrads! (October 2023)
- April 17, 2023
Yale Allergy & Immunology Presents at AAAAI
Get In Touch
Contacts
Email